Trouble in IPO Land

The shares of several companies that recently went public are down by double-digit percentages from their official pricing.

Qilai Shen/Bloomberg

Qilai Shen/Bloomberg

A fledgling biopharma company that went public last week with at least a half dozen hedge fund investors has seen its stock mauled in its first two trading days.

Pyxis Oncology Thursday priced its initial public offering of 10.5 million shares at $16 per share.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.